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1.1 What is COVID-19?
SARS-CoV-2, better known as COVID-19, is an infectious respiratory disease with influenza-like
symptoms. Per April 13th, 2021, the disease has more than 136 000 000 confirmed cases and almost 3
000 000 confirmed deaths worldwide [1]. The number of infected is expected to be much higher since
most countries only test people in risk groups or people who have been in contact with someone
with the virus. It originated in Wuhan, China, in November or December 2019 and has spread
globally, with massive outbreaks, especially in Italy and Spain in early 2020, later in the United
States, and most recently in India. Most countries introduced some measures to limit spread and
importation. In Norway, schools, kindergartens and universities closed on March 13th, 2020. With
kindergartens reopening up April 20th, schools up to the 4th grade reopening on April 27th, 2020,
and the rest of schools opening again May 11th, 2020. Other measures have been closing borders
for tourists, quarantine for travelers from other countries, closing bars and restaurants, limits on
the size of events, among other things.
Four different vaccines are accepted by the European Medicine Agency(EMA) and the Nor-
wegian medicine agency. Those are the RNA-vaccines Vaccine Moderna and Comirnaty (from
BioNTech/Pfizer), the virus vector vaccines Vaczevria from AstraZeneca, and Janssen-Cilag vac-
cine. None of the virus vector vaccines are in use in Norway as of May 12th because of links to
rare blood-clot complications, low amounts of platelets, and bleedings. The vaccines also have some
less serious side effects like fever, headaches, tiredness, and pain in muscles and joints [15]. Some
countries have gotten further than others in their vaccination efforts; large countries with a high
degree of vaccination per May 20th, 2021 are Israel (58.1% fully vaccinated), Chile (39.5%), USA
(37.3%), and the UK (30.7%). Some poorer countries are lagging in vaccine coverage, most notably
India (10.4% at least one dose 2.9% fully vaccinated) and many African countries risking significant
outbreaks in the near future.
Currently, there is a massive outbreak in India, Peaking at more than 400 000 new cases per
day and a total of almost 4 700 000 registered cases in the last 14 days (May 6th - May 19th, 2021).
The first vaccine in Norway was administered on December 27th, 2020. By May 20th, 2021,
12.63% of the Norwegian population have received both vaccine doses, while 29.50% have received
at least one of the two doses. In Norway, we have prioritized older adults and Health Care/Elderly
care Workers to get the vaccine first. Estimates for when every person aged 18+ in Norway is offered
at least the first dose of the vaccine varies from late July to early August for the most optimistic
scenarios. More realistic scenarios point to early September.
A CDC study [2] of vaccine efficacy in health care professionals, first responders, and other
essential workers shows that the mRNA vaccines reduce the risk of getting infected by COVID-19
by 80% two weeks after the first dose. The efficacy increases to 90% two weeks after the second
dose, which is higher than estimates from similar studies in the UK and Israel, which show about
70 and 60 % lowered chance of getting infected after the first dose.
Vaccines make this pandemic much easier to handle if we compare it to the 1918 H1N1 pandemic
(the Spanish flu) [3], where 500 million people were infected (1/3 of the world’s population), and
around 50 million people died. With a successful vaccination effort, it seems likely that the total
COVID-19 cases will be much lower despite the world population increasing five-fold.
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1.2 What do we investigate in this thesis?
In this thesis, we investigate vaccination strategies for COVID-19. The two strategies we are testing
are (i) prioritizing old, vulnerable people and (ii) prioritizing younger people with the most contacts.
We measure success by looking at the number of deaths and years of life lost (YLL) for each scenario.
Other interesting aspects we could have taken into consideration are the number of infections, the
length of the pandemic, and hospitalizations. Other than that, investigating the consequences of
lock-downs, economic burden, and the population’s physical and mental health burden could be
interesting things to study.
1.3 Summary of methods
We use an Individual-based model (IBM), which models each individual with age and their contacts,
creating a network in a community. Some individuals start with being infected and infectious, while
the rest are susceptible to the disease. As time passes, each infectious individual has a chance of
infecting its contacts with a probability p, and everyone that gets infected has an incubation time
of three days before becoming infectious for five days. Adding a vaccine into this model makes it so
the vaccinated people can not be infected or infectious and are practically taken out of the network
together with the people that are recovered or dead.
1.4 Short summary of results
The safest and most consistently optimal vaccine strategy for COVID-19 is vaccinating the oldest
and most vulnerable people first. However, there are some scenarios where vaccinating the people
with the most contacts could be optimal.
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2 Basic mathematical theory of vaccination
There are two main types of models used to model the spread of infectious diseases, Individual-based
models (IBMs) and compartmental models (typically SIR or SEIR models).
IBMs are used in this thesis. These modes have become more popular recently as computers
with more processing power have become available.
Compartmental models [4] were developed by Daniel Bernoulli when modelling smallpox in the
18th century, and refined by Kermack and McKendrick in the 20th century. In these models one
partitions the polulation into compartments of susceptible, infected and recovered (SIR). In the
simplest SIR-models, infected individuals infect susceptible people at a rate β that depends on the
number of infected/infectious individuals and susceptible individuals. After infection, individuals















The equations describe the evolution of the infectious disease over time. There are several options
for expanding the model. For instance, by introducing a new compartment, the exposed. Individuals
exposed to the disease will either go back to being susceptible or become infected (This is called an
SEIR model.) One can also include death rates (both from disease and natural deaths) and birth
rates to the society, vaccines (taking people from the susceptible compartment to the recovered
compartment). Another option is to split the compartment by age groups and to introduce social
contact matrices to describe the level of social contact between different age groups.
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3 Other studies of vaccination
Vaccination strategies for transmissible diseases are extensively studied using mathematical models.
Moore et al. [5] use an SEIR (susceptible, exposed, infected, recovered) of COVID-19 model and
social contact matrices to test different vaccine strategies. They considered the UK population and
vaccines with varying effects. They measure both deaths and Quality Adjusted Life Years (QALYs)
losses. The different vaccines they have tested are reduction in susceptibility (type 1), reduction
in becoming symptomatic (type 2), and reduction in experiencing severe symptoms (type 3). They
also introduce comorbidities, individuals with pre-existing conditions that make them more likely to
die from COVID-19, and healthcare workers, who are much more likely to get exposed to COVID-
19 than the average in the age group. For each vaccine, Moore et al. test three different vaccine
strategies. The first strategy is vaccinating by age group (80+,60+,40+,20+, and the rest).
The second strategy is vaccinating by age group and including comorbidities as a separate group
(comorbidities,80+,60+,40+,20+, and rest). The third strategy is vaccinating evenly across all age
groups. In all scenarios, the evenly distributed vaccine leads to significantly more deaths than the
other strategies. In all the scenarios, the best strategy is to vaccinate by age; when introducing
comorbidities, they find that for a low level of social distancing measures, comorbidities should be
put after the 80+ group for vaccines 1 and 2. For vaccine 3, they should be put after 60+, and with
no social-distancing measures, comorbidities should come after the 60+ group. For all scenarios,
the optimal strategy is very similar, both when considering deaths and QALYs lost. This result is
expected considering the morbidity in the older age groups is much higher compared to younger
age groups. When adding healthcare workers for vaccine 1, they should be prioritized after the
80+ group. At the same time, they argue that they might have lower priority for vaccines 2 and
3 because those do not significantly lower the transmission rate for the average healthcare worker.
They check vaccines with different efficacies (50%,70+%, and 90%) and find that with a vaccine
with 50% efficacy, they need to vaccinate 70% (all 20+) of the population in their scenario to avoid
a significant second wave. In contrast, with a 70-90% efficacy, they can avoid a second outbreak
with only 40%(40+) coverage.
MacIntyre et al. [6] use an SEIR model to study vaccine strategies in New South Wales, Aus-
tralia. They consider both a limited supply of 1 million vaccines, and an unlimited supply of
vaccines, with the capacity of vaccinating 50 000 - 300 000 people per day. For most of this study,
it is assumed a vaccine efficacy of 90%. The strategies they test are: giving 1 million doses to
targeted age groups (65+, 10-29 and Healthcare workers + 10-29), giving 1 million doses through
ring vaccination, which requires contact tracing, and vaccination of contacts, and mass vaccination
with a supply big enough for the whole population of New South Wales, with different priorities
(oldest first, young people first and healthcare workers, then young people). Their findings are that
vaccinating the young will significantly limit the spread of the virus compared to vaccinating older
adults, but vaccinating older adults would still lead to fewer deaths since they have a much higher
risk of dying from COVID-19. For ring vaccination, they tested varying success in contact tracing,
70%, 80%, and 90%, with a reduction in efficacy from 90% to 45%. They found that with a limited
supply, successful ring vaccination leads to way fewer cases and deaths. With an unlimited supply
of vaccines, the interesting part of the study is the speed of vaccination and vaccine efficacy. They
tested 50 000, 75 000, 100 000, 125 000, and 300 000 doses per day, where 125 000 is the estimated
maximum of what the health care system in New South Wales could realistically do. They find
that 50 000 doses per day would lead to a significantly larger outbreak than 75 000 doses per day,
and 100 000 would lead to about half the outbreak size compared to 75 000 doses per day. Varying
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vaccine efficacy, with 125 000 doses per day, showed led to significant differences in results. For
herd immunity they use the formula Vc = 1Ve ∗ (1−
1
R0
) with R0 = 2.5 Ve is vaccine efficacy and Vc
is vaccine coverage. They find that herd immunity with a vaccine efficacy of 60% they need 100%
vaccine coverage, while 90% one would only need vaccine coverage of 66%.
Dubé et al. [11] use a Personal Contact Network (PCN) to study the spread of an epidemic,
looking at both size and length of an outbreak and the effects of different vaccine strategies. They
are looking at static networks, networks that do not change after the vaccine is deployed, and
evolving networks that change as the vaccine is deployed. The vaccine strategies they looked at are
random vaccination, high degree vaccination (vaccinating individuals with the most contacts), ring
vaccination, and no vaccination. They tested for many different networks and found the 30 networks
that give the most prolonged epidemic outbreak and the 30 that gave the most infections. The results
show that for static networks, ring vaccination and high degree vaccination performs similarly in
most scenarios, both significantly better than random vaccination when it comes to the length of
the epidemic. At the same time, the results are somewhat inconclusive when it comes to the size
of the epidemic, with ring vaccination either performing poorly or with high variance. For evolving
graphs, high degree vaccination slightly outperforms random vaccination, while ring vaccination
performs poorly. This result is not necessarily intuitive but can be interpreted as vaccinating too
much in an area that leaves large parts of the network unvaccinated and vulnerable to outbreaks
due to an evolving network.
Bubar et al. [7] use an age-stratified SEIR-model with an age-based social contact matrix to
model different vaccination strategies, looking at a number of incidents, mortality, and YLL. For
vaccination strategies, they tested prioritizing children and teenagers, 20-49 year-olds, 20+, 60+ and
everyone evenly. For most of the study, they considered a vaccine efficacy of 90% vaccination speed
of 0.2% of the population per day and the reproduction number R varying between 1.1 and 2.0.
They also have a vaccine hesitancy factor making it such that a maximum of 70% from any age group
is eligible to take the vaccine. With R > 1.2 and vaccine speed of 0.1% and 0.2% of the population,
they find that one should always prioritize older adults, while if R0 < 1.2 we could consider either
the 20-49 or 20+ strategy. They also tested for different population and social contact networks in
9 different countries, with R0 = 1.5 again the 60+ strategy is optimal, while there were different
optimal strategies for the different countries with R0 = 1.15. Introducing age-dependent vaccine
efficacy with decreasing efficacy at older ages reduced the effect of vaccinating older adults first.
However, they still found that prioritizing 60+ still was the optimal strategy with R0 = 1.5.
Folkehelseinstituttet (FHI, the Norwegian Institute of Public Health) has been tasked with
investigating the effects of geographical prioritization of vaccines to areas in Norway with a high
spread of infection like Oslo county and some municipalities in Viken county [9]. They use both
individual-based models and SEIR models to check if such a strategy would be efficient compared
to even geographical distribution based on population. They have considered both geographical
prioritizations until everyone above 65 and healthcare workers have been offered a vaccine in the
prioritized areas. Everyone above age 45 and healthcare workers have been offered a vaccine. R
varies from 0.8-1.3. They also try scenarios with a new 50% more contagious disease mutation
from April 1st, 2021. The results in both models with geographical prioritization to Oslo give
considerably less burden of disease for large R or a more contagious virus from April 1st. The
effect on hospitalization is smaller but still noticeable. The new, more contagious virus always
leads to more disease, not surprisingly, as there are no new measures taken for the mutated virus.
When prioritizing Oslo and Viken county, the reduction in disease and deaths is less than when
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only prioritizing Oslo county, which could be attributed to it not considering the prioritization of
municipalities in Viken with high infection over municipalities with low infection. When prioritizing
until individuals older than 45 years and healthcare workers have been offered a vaccine, the number
of deaths sometimes increases nationally, which could be attributed to at-risk groups in other places
of the country having their vaccine postponed for too long.
Di Ruscio et al. [10] used an IBM to look at the spread of Methicillin-resistant Staphyloccocus
aureus (MRSA) in a low prevalence country such as Norway. They have 5 million nodes in the
network; each node has an associated age, ethnic background, occupation, hospitalization status,
and epidemiological status. A network of contacts is built based on the Norwegian national registry
(2008-2015) and household prevalence data. Each node has a chance to get infected at time t based
on whether someone infectious is nearby and based on data of chance of infection in the current
setting(work, school, home, hospital, nursing home). Running the model, they found a reproduction
number Re = 0.68(95%CI0.47− 0.90), which means that the virus would be eradicated in Norway
without importing MRSA from abroad. There will still be some outbreaks with imports, while




4 Description of the model
4.1 The transmission model
Our model uses a population of size n with assigned ages consistent with the age distribution in
Norway. Each individual has a number of contacts determined by a random graph distribution.
The random graphs are generated using a built-in routine in the Mathematica software. Our age-
assignment algorithm ensures that the most contacts are in the age range 16-44 years. We start
the model experiments with two infected and infectious individuals with a probability p of infecting
each contact each day. Every individual that gets infected has an incubation time of 3 days where
they are not infectious. After three days, they are infectious for five days, where they, for each day,
have a probability p of infecting each contact for the next five days if their contacts are not yet
infected or vaccinated. For each day, we calculate newly infected people; for each susceptible person
i, the chance of getting infected is pi = 1− (1− p)n where n is the number of infectious contacts.
4.2 Modelling vaccination
A vaccine is given to a random (Poisson distributed integer) number of individuals each day. In
our experiments, we vary the vaccination rate from 0.01 to 10.01 per day. We explore two different
vaccination strategies. The first strategy is to vaccinate the people with the most contacts first to
try to limit the outbreak as much as possible. The second strategy is to vaccinate the oldest people
first to protect the most vulnerable people. We compare the number of expected deaths and the
YLL. Comparing these numbers could tell us if we should prioritize vaccinating older adults first or
people with lots of contacts.
4.3 Modelling deaths and years-of-life lost
For estimating deaths, we use the Center for Disease Controls (CDCs) data on relative probability
for dying from COVID-19 [12]. These data are presented in table 1. The raw data is interpolated
using a built-in interpolation function in Mathematica using the center value of each age group. We
also added extra numbers at age 0 (we used 1/9 relative to the age group 18-29 years) and at age
100 (we used 1000 relative to 18-29 years). The result is the graph in figure 1. This function gives
the probability for each age to die from COVID-19 compared to an 18-29-year-old, which we set
this to be 0.1%. Our results are insensitive to this choice since it only scales the number of deaths
by a factor and relative numbers. We run the model and record who gets infected with COVID-19
and then sum the chances of every infected person at the end of the run dying. This analysis gives




Ii ·D(agei) , (4)
where Ii is 1 if person i was ever infected and 0 if not, D(agei) is chance of dying for a person of
the age agei, and agei is the age of person i.
To get the expected number of years of life lost, we need the expected years of life remaining.
To do this, we use the expected years of life remaining in Sweden [13], which should be similar to
Norway, and the life expectancy at birth in Norway, found in table 2. We again take the center
value for each age range and fit a 4th-degree polynomial to get the expected years of life left for
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Figure 1: The relative chance of dying from COVID-19 based on age compared to an 18-29 year-old
based on interpolated data from the CDC
each age, resulting in the graph in figure 2. The reason for using a 4th-degree polynomial is that
we expect the life expectancy to increase the most towards the later ages; someone going from 2 to
7 years old is not going to increase their expected age drastically, but someone going from 95 to 99
years old they already exceeded their expected age at 95. Then the years of life lost for each person




Ii ·D(agei) · LE(agei) (5)
where LE(agei) is the remaining life expectancy of a person at agei.
4.4 The basic reproduction number
The basic reproduction number R0 describes how many people one infectious person is expected to








where p is the probability for an infectious person to infect a contact in a day, E(D) is the expected
value of number of contacts for a person in the IBM, and V (D) is the variance in number of contacts
in the IBM. This gives us a formula for p given R0:
p =
R0
E(D) + V (D)−E(D)E(D)
. (7)
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Figure 2: The expected years of life remaining based on age fitted to a 4th degree polynomial based
on data from SCB
4.5 Model runs
We run our model 5 times for each initial condition and find the number of deaths and YLL for
each starting condition. We then find the 95% confidence intervals for different vaccine paces for
each starting condition. We run it with populations of n = 300 and n = 1000 and R0 = 1.5 and
R0 = 1.15, vaccine pace varying from 0.01 per day to 10.01 per day, using Watts-Strogatz Graph
Distribution, Barabasi-Albert Graph Distribution, Uniform Graph Distribution, and Spatial Graph
Distribution.
4.6 Description of network models
Our models use four different types of random graphs to generate synthetic contact networks: Spatial
Graph Distributions, Barabasi-Albert Graphs, Uniform Graph Distributions, and Watts-Strogatz
Graphs.
In the Spatial Graph Distribution, we have n nodes uniformly distributed on a unit square and
a maximum distance r for how far two connected nodes can be apart. This set-up is well-suited for
simulating families. Disease spread through these networks is slow for small values of r.
The Barabasi-Albert Graphs start with a number m0 of nodes. Nodes are added one by one,
assigning new node links to the already existing nodes, with a higher probability of linking to nodes
with many contacts. This set-up is well-suited for simulating highly social people in a community
since they are more likely to have lots of contacts but might not describe typical family structures
in the network.
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Figure 3: A population with the Uniform Graph Distribution, with n = 100
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Figure 4: A population with the Spatial Graph Distribution, with n = 100
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Figure 5: A population with the Watts-Strogatz Graph Distribution, with n = 100
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Figure 6: A population with the Barabasi-Albert Graph Distribution, with n = 100
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Table 1: The chance of dying from COVID-19 relative to a 18-29 year old according to data from
the CDC






Table 2: Life expectancy used in this work, at age 0 is life expectancy in Norway, while the rest of
the data is years of expected life left for Sweden
In a Uniform Graph Distribution, we give some n nodes and m number of total connections for
the network. Every connection has an equal chance of existing.
In the Watts-Strogatz model, we start with n nodes where every node initially is connected to m
nodes to the left of itself and m nodes to the right. Then we give a probability p that any connection
between two nodes is broken and replaced with another random connection. This network is well-
suited for simulating families if p is not too high since many groups of three or four nodes connected,
with some random nodes are connected, representing schools or workplaces.
Illustrations of the different types of graphs are shown in figures 3, 4, 5 and 6.
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5 Results
Looking at deaths and YLL for the Uniform, Spatial or Watts-Strogatz Graph Distributions with a
population n = 300 and basic reproduction number R0 = 1.5 (figures 7, 8 and 9) we see significant
differences between the different vaccination strategies. Vaccinating older adults first is far superior
to vaccinating the ones with most contacts first.
Generally, there are slightly fewer cases when vaccinating the ones with the most contacts (figures
23, 24 and 26), but not enough to compensate for the increased risk of severe disease and death in
the most vulnerable groups.
Increasing the population to n = 1000 and/or lowering the basic reproduction number to R0 =
1.15 does not change the results significatly (figures 11, 12, 13, 15, 16, 17, 19, 20 and 21). We can see
in figures 27, 28, 30, 31, 32, 34, 35, 36, and 38 that there are generally fewer cases when vaccinating
the ones with the most contacts, but again, it is not enough to compensate for the increased risk of
dying from COVID-19 in the older parts of the population.
For the Barabasi-Albert Graph Distribution with a population of n = 300 and basic reproduction
number R0 = 1.5 (figure 10) the number of deaths is slightly higher for vaccinating the ones with
the most contacts. However, the YLL is very similar for both vaccination strategies. The number
of cases in figure 25 shows a significant difference for higher vaccination numbers. This difference
is enough to compensate for the increased mortality of the older population.
Increasing the population to n = 1000 and/or lowering the basic reproduction number to R0 =
1.15 (figures 14, 18, and 22) gives similar number of deaths. In contrast, YLL is noticeably lower in
all 3 scenarios when vaccinating the ones with the most contacts. Looking at the number of cases
in figures 29, 33, and 37, we see a huge drop in number of cases for higher vaccination rates, almost
ending the outbreak entirely.
For the 95% confidence intervals, we see across all figures that the uncertainty is consistently
smaller when vaccinating older adults first compared to vaccinating the ones with the most contacts
first. This result is likely because vaccinating older adults first is aimed at protecting them, and
since they have few contacts, it does not do much to stop or limit the outbreak. While vaccinating
young people first aims to stop or limit the outbreak as much as possible. If it is successful in one
run and unsuccessful in another, it makes the uncertainty of the strategy higher.
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Figure 7: The red lines are when we vaccinate the people with the most contacts while blue are
when we vaccinate old people first. The middle line for each color is the mean value, while the
upper and lower line shows the 95% confidence interval. In figure A we see the number of deaths
and in B we see the number of YLL with the Uniform Graph Distribution with R0 = 1.5 and a
population n = 300.
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Figure 8: The red lines are when we vaccinate the people with the most contacts while blue are
when we vaccinate old people first. The middle line for each color is the mean value, while the upper
and lower line shows the 95% confidence interval. In figure A we see the number of deaths and in
B we see the number of YLL with the Spatial Graph Distribution with R0 = 1.5 and a population
n = 300.
Figure 9: The red lines are when we vaccinate the people with the most contacts while blue are
when we vaccinate old people first. The middle line for each color is the mean value, while the
upper and lower line shows the 95% confidence interval. In figure A we see the number of deaths
and in B we see the number of YLL with the Watts-Strogatz Graph Distribution with R0 = 1.5 and
a population n = 300.
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Figure 10: The red lines are when we vaccinate the people with the most contacts while blue are
when we vaccinate old people first. The middle line for each color is the mean value, while the
upper and lower line shows the 95% confidence interval. In figure A we see the number of deaths
and in B we see the number of YLL with the Barabasi-Albert Graph Distribution with R0 = 1.5
and a population n = 300.
Figure 11: The red lines are when we vaccinate the people with the most contacts while blue are
when we vaccinate old people first. The middle line for each color is the mean value, while the
upper and lower line shows the 95% confidence interval. In figure A we see the number of deaths
and in B we see the number of YLL with the Uniform Graph Distribution with R0 = 1.15 and a
population n = 300.
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Figure 12: The red lines are when we vaccinate the people with the most contacts while blue are
when we vaccinate old people first. The middle line for each color is the mean value, while the upper
and lower line shows the 95% confidence interval. In figure A we see the number of deaths and in
B we see the number of YLL with the Spatial Graph Distribution with R0 = 1.15 and a population
n = 300.
Figure 13: The red lines are when we vaccinate the people with the most contacts while blue are
when we vaccinate old people first. The middle line for each color is the mean value, while the
upper and lower line shows the 95% confidence interval. In figure A we see the number of deaths
and in B we see the number of YLL with the Watts-Strogatz Graph Distribution with R0 = 1.15
and a population n = 300.
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Figure 14: The red lines are when we vaccinate the people with the most contacts while blue are
when we vaccinate old people first. The middle line for each color is the mean value, while the
upper and lower line shows the 95% confidence interval. In figure A we see the number of deaths
and in B we see the number of YLL with the Barabasi-Albert Graph Distribution with R0 = 1.15
and a population n = 300.
Figure 15: The red lines are when we vaccinate the people with the most contacts while blue are
when we vaccinate old people first. The middle line for each color is the mean value, while the
upper and lower line shows the 95% confidence interval. In figure A we see the number of deaths
and in B we see the number of YLL with the Uniform Graph Distribution with R0 = 1.5 and a
population n = 1000.
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Figure 16: The red lines are when we vaccinate the people with the most contacts while blue are
when we vaccinate old people first. The middle line for each color is the mean value, while the upper
and lower line shows the 95% confidence interval. In figure A we see the number of deaths and in
B we see the number of YLL with the Spatial Graph Distribution with R0 = 1.5 and a population
n = 1000.
Figure 17: The red lines are when we vaccinate the people with the most contacts while blue are
when we vaccinate old people first. The middle line for each color is the mean value, while the
upper and lower line shows the 95% confidence interval. In figure A we see the number of deaths
and in B we see the number of YLL with the Watts-Strogatz Graph Distribution with R0 = 1.5 and
a population n = 1000.
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Figure 18: The red lines are when we vaccinate the people with the most contacts while blue are
when we vaccinate old people first. The middle line for each color is the mean value, while the
upper and lower line shows the 95% confidence interval. In figure A we see the number of deaths
and in B we see the number of YLL with the Barabasi-Albert Graph Distribution with R0 = 1.5
and a population n = 1000.
Figure 19: The red lines are when we vaccinate the people with the most contacts while blue are
when we vaccinate old people first. The middle line for each color is the mean value, while the
upper and lower line shows the 95% confidence interval. In figure A we see the number of deaths
and in B we see the number of YLL with the Uniform Graph Distribution with R0 = 1.15 and a
population n = 1000.
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Figure 20: The red lines are when we vaccinate the people with the most contacts while blue are
when we vaccinate old people first. The middle line for each color is the mean value, while the upper
and lower line shows the 95% confidence interval. In figure A we see the number of deaths and in
B we see the number of YLL with the Spatial Graph Distribution with R0 = 1.15 and a population
n = 1000.
Figure 21: The red lines are when we vaccinate the people with the most contacts while blue are
when we vaccinate old people first. The middle line for each color is the mean value, while the
upper and lower line shows the 95% confidence interval. In figure A we see the number of deaths
and in B we see the number of YLL with the Watts-Strogatz Graph Distribution with R0 = 1.15
and a population n = 1000.
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Figure 22: The red lines are when we vaccinate the people with the most contacts while blue are
when we vaccinate old people first. The middle line for each color is the mean value, while the
upper and lower line shows the 95% confidence interval. In figure A we see the number of deaths
and in B we see the number of YLL with the Barabasi-Albert Graph Distribution with R0 = 1.15
and a population n = 1000.
Figure 23: The average number of new cases each day with Spatial Graph Distribution with n = 300
and R0 = 1.5. The red line shows new cases when vaccinating the ones with the most contacts,
while the blue line is when vaccinating old people first. Each graph is for one vaccine-pace from
0.01 per day in the top left to 10.01 in the bottom right.
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Figure 24: The average number of new cases each day with Watts-Strogatz Graph Distribution with
n = 300 and R0 = 1.5. The red line shows new cases when vaccinating the ones with the most
contacts, while the blue line is when vaccinating old people first. Each graph is for one vaccine-pace
from 0.01 per day in the top left to 10.01 in the bottom right.
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Figure 25: The average number of new cases each day with Barabasi-Albert Graph Distribution
with n = 300 and R0 = 1.5. The red line shows new cases when vaccinating the ones with the most
contacts, while the blue line is when vaccinating old people first. Each graph is for one vaccine-pace
from 0.01 per day in the top left to 10.01 in the bottom right.
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Figure 26: The average number of new cases each day with Uniform Graph Distribution with
n = 300 and R0 = 1.5. The red line shows new cases when vaccinating the ones with the most
contacts, while the blue line is when vaccinating old people first. Each graph is for one vaccine-pace
from 0.01 per day in the top left to 10.01 in the bottom right.
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Figure 27: The average number of new cases each day with Spatial Graph Distribution with n = 300
and R0 = 1.15. The red line shows new cases when vaccinating the ones with the most contacts,
while the blue line is when vaccinating old people first. Each graph is for one vaccine-pace from
0.01 per day in the top left to 10.01 in the bottom right.
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Figure 28: The average number of new cases each day with Watts-Strogatz Graph Distribution with
n = 300 and R0 = 1.15. The red line shows new cases when vaccinating the ones with the most
contacts, while the blue line is when vaccinating old people first. Each graph is for one vaccine-pace
from 0.01 per day in the top left to 10.01 in the bottom right.
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Figure 29: The average number of new cases each day with Barabasi-Albert Graph Distribution
with n = 300 and R0 = 1.15. The red line shows new cases when vaccinating the ones with the most
contacts, while the blue line is when vaccinating old people first. Each graph is for one vaccine-pace
from 0.01 per day in the top left to 10.01 in the bottom right.
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Figure 30: The average number of new cases each day with Uniform Graph Distribution with
n = 300 and R0 = 1.15. The red line shows new cases when vaccinating the ones with the most
contacts, while the blue line is when vaccinating old people first. Each graph is for one vaccine-pace
from 0.01 per day in the top left to 10.01 in the bottom right.
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Figure 31: The average number of new cases each day with Spatial Graph Distribution with n = 1000
and R0 = 1.5. The red line shows new cases when vaccinating the ones with the most contacts,
while the blue line is when vaccinating old people first. Each graph is for one vaccine-pace from
0.01 per day in the top left to 10.01 in the bottom right.
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Figure 32: The average number of new cases each day with Watts-Strogatz Graph Distribution with
n = 1000 and R0 = 1.5. The red line shows new cases when vaccinating the ones with the most
contacts, while the blue line is when vaccinating old people first. Each graph is for one vaccine-pace
from 0.01 per day in the top left to 10.01 in the bottom right.
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Figure 33: The average number of new cases each day with Barabasi-Albert Graph Distribution
with n = 1000 and R0 = 1.5. The red line shows new cases when vaccinating the ones with the most
contacts, while the blue line is when vaccinating old people first. Each graph is for one vaccine-pace
from 0.01 per day in the top left to 10.01 in the bottom right.
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Figure 34: The average number of new cases each day with Uniform Graph Distribution with
n = 1000 and R0 = 1.5. The red line shows new cases when vaccinating the ones with the most
contacts, while the blue line is when vaccinating old people first. Each graph is for one vaccine-pace
from 0.01 per day in the top left to 10.01 in the bottom right.
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Figure 35: The average number of new cases each day with Spatial Graph Distribution with n = 1000
and R0 = 1.15. The red line shows new cases when vaccinating the ones with the most contacts,
while the blue line is when vaccinating old people first. Each graph is for one vaccine-pace from
0.01 per day in the top left to 10.01 in the bottom right.
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Figure 36: The average number of new cases each day with Watts-Strogatz Graph Distribution with
n = 1000 and R0 = 1.15. The red line shows new cases when vaccinating the ones with the most
contacts, while the blue line is when vaccinating old people first. Each graph is for one vaccine-pace
from 0.01 per day in the top left to 10.01 in the bottom right.
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Figure 37: The average number of new cases each day with Barabasi-Albert Graph Distribution
with n = 1000 and R0 = 1.15. The red line shows new cases when vaccinating the ones with
the most contacts, while the blue line is when vaccinating old people first. Each graph is for one
vaccine-pace from 0.01 per day in the top left to 10.01 in the bottom right.
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Figure 38: The average number of new cases each day with Uniform Graph Distribution with
n = 1000 and R0 = 1.15. The red line shows new cases when vaccinating the ones with the most
contacts, while the blue line is when vaccinating old people first. Each graph is for one vaccine-pace
from 0.01 per day in the top left to 10.01 in the bottom right.
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6 Discussion and conclusions
The strategy of prioritizing older adults outperforms the alternative strategy across experiments
using the Spatial, Uniform, and Watts-Strogatz Graph Distributions regardless of whether R0 = 1.5
or R0 = 1.15, and whether and n = 300 or n = 1000. It can be viewed as the safest solution based
on this model.
For the Barabasi-Albert Graph Distribution, we see potential situations where vaccinating those
with the most contacts first is the better strategy. The Barabasi-Albert Graph Distribution is also
the graph distribution that creates the network with super-spreaders. Hence, it is reasonable that
vaccinating the people with the most contacts performs better for this graph. Whether it is realistic
or not is another question.
The results from this model show that the safest strategy is to vaccinate the most vulnerable
first. Vaccinating the people with the most contacts is a potentially high-risk, high-reward strategy.
It has the potential to stop the outbreak, but the costs if it fails are potentially high.
The strengths of this study are that we have tested this model for many different networks. We
have tested it for many different vaccination rates for each network, running it multiple times for
each scenario.
Potential weaknesses of this study are that we have only tried this for relatively small popula-
tions. The networks are not based on any real-life data and could be unrealistic.
We have also assumed perfect information; we know who has the most contacts, which would
require detailed surveillance data in a real-world scenario. We also make the unrealistic assumption
that as soon as an individual is infected, he/she is removed from the vaccine queue. We also assume
that the vaccine has 100% efficacy, and there is no vaccine hesitancy in our populations.
Possible future work with this model includes making networks based on real-life data and
looking at other measurements for success, like Quality-adjusted YLL. We can also study hospital-
izations. High hospitalization numbers can make the pandemic more deadly due to limits in the
health care system’s capacity.
It is also possible to add different settings, with different contacts at different times of the day,
adding smaller time-steps, and adding variables like school, work, and household contacts. We
can also fix weaknesses mentioned previously, like defect vaccines, either in all or nothing vaccine





Everything is coded using Wolfram Mathematica version 12.1 and 12.2





H = UniformGraphDistribution[n, 4*n];
(*H = WattsStrogatzGraphDistribution[300,0.15,5];*)
(*H=DegreeGraphDistribution[Table[3,n]];*)
dødelighet = {{0, 1/9.}, {Mean[Range[0, 4]], 1/9.}, {Mean[Range[5, 17]],
1/16.}, {Mean[Range[18, 29]], 1.}, {Mean[Range[30, 39]],
4.}, {Mean[Range[40, 49]], 10.}, {Mean[Range[50, 64]],
30.}, {Mean[Range[65, 74]], 90.}, {Mean[Range[75, 84]],
220.}, {Mean[Range[85, 99]], 630.}, {100, 1000.}};
d = Interpolation[dødelighet];
aldersfordeling =
Round[n*{54827, 296332, 451246, 191130, 255214, 1789814, 1501597, 596710,
185480, 45230}/5367580.];
gruppe1 = {0};
gruppe2 = Range[1, 5];
gruppe3 = Range[6, 12];
gruppe4 = Range[13, 15];
gruppe5 = Range[16, 19];
gruppe6 = Range[20, 44];
gruppe7 = Range[45, 66];
gruppe8 = Range[67, 79];
gruppe9 = Range[80, 89];
gruppe10 = Range[90, 100];
grupper = {gruppe1, gruppe2, gruppe3, gruppe4, gruppe5, gruppe6, gruppe7,
gruppe8, gruppe9, gruppe10};
levedata = {{0, 82.5}, {(50 + 64)/2, 27.5}, {(65 + 79)/2, 15.6}, {(80 + 89)/2,
7.0}, {(90 + 99)/2, 2.5}};
gg = Fit[levedata, {zz^4, zz, 1}, zz];
pl1 = ListPlot[levedata];















links = Drop[ArrayRules[A][[All, 1]], -1];
L[i_] :=
Map[{#} &,
Extract[links, Position[links[[All, 1]], _?(# == i &)]][[All, 2]]];
antallkontakter = Table[Length[L[i]], {i, 1, n}];
G = (Mean[





RandomChoice[grupper[[k]], aldersfordeling[[k]]], {k, 1, 10}]];
alder = {};




alder = Append[alder, RandomChoice[Join[gruppe5, gruppe6]]];
,
alder = Append[alder, RandomChoice[alder0]];
];
, {k, 1, Length[alder0]}];
forventetlevetid = gg /. zz -> alder;








smittende = Table[0, {n}];
k = RandomInteger[{1, n}];
smittende[[k]] = 1;




psmittende = Position[smittende, _?(# == 1 &)];
farge = Map[# -> Red &, Flatten[psmittende]];
plotliste = Append[plotliste, GraphPlot[g, VertexStyle -> farge]];




Prepend[Table[Table[0, {n}], {smittsomtid - 1}], smittende];
Do[
vaksinerperdag = RandomInteger[PoissonDistribution[vaksinerate]];
ksmitte = Flatten[Position[smittende, _?(# == 1 &)]];
nyimune = smittende;
vaksineliste = Reverse[SortBy[Delete[alderwp, pimune], First]];
If[Length[vaksineliste] >= vaksinerperdag,
Do[
nyimune[[vaksineliste[[kk, 2]]]] = 1;
vaksinert = Append[vaksinert, vaksineliste[[kk, 2]]];
, {kk, 1, vaksinerperdag}];
,
nyimune = Table[1, {n}];
];
imune = UnitStep[imune + nyimune - 1];
mulige =
Plus @@ Table[
MapAt[# + 1 &, Table[0, {n}], L[ksmitte[[j]]]], {j, 1,
Length[ksmitte]}];
probsmitte = 1 - (1 - \[Beta])^mulige;
probsmitte = probsmitte*(1 - imune);
If[Length[ksmitte] > 0 ,
nysmittede =
UnitStep[Sign[probsmitte - Table[RandomReal[], {Length[mulige]}]]];
nysmittede = UnitStep[nysmittede - smittetever - 1];
smittetever = UnitStep[smittetever + nysmittede - 1];
smittende =
smittende + UnitStep[Last[nysmittedeliste] - 1] - Last[smittendeliste];
smittendeliste = Drop[smittendeliste, -1];
smittendeliste = Prepend[smittendeliste, Last[nysmittedeliste]];
nysmittedeliste = Drop[nysmittedeliste, -1];
nysmittedeliste = Prepend[nysmittedeliste, nysmittede];
pnysmittende = Position[nysmittede, _?(# == 1 &)];
psmittende = Position[smittende, _?(# == 1 &)];
pimune = Position[imune, _?(# == 1 &)];
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nyetilfeller = Append[nyetilfeller, Plus @@ nysmittede];
,
smittende =
smittende + UnitStep[Last[nysmittedeliste] - 1] - Last[smittendeliste];
smittendeliste = Drop[smittendeliste, -1];
smittendeliste = Prepend[smittendeliste, Last[nysmittedeliste]];
nysmittede = Table[0, {n}];
nyetilfeller = Append[nyetilfeller, 0];
nysmittedeliste = Drop[nysmittedeliste, -1];







, {t, 1, tmax}];
referanse = 0.001;
døde = Plus @@ (referanse*d[alder]*smittetever);
taptelevear = Plus @@ (referanse*d[alder]*smittetever*forventetlevetid);
dliste = Append[dliste, døde];
lliste = Append[lliste, taptelevear];
nyetilfellerliste = Append[nyetilfellerliste, nyetilfeller];
, {teller, 1, 5}];
dødsliste = Append[dødsliste, {v, dliste}];
levearliste = Append[levearliste, {v, lliste}];




Table[Map[Mean[# + 0.] &,
Transpose[Partition[nyetilfellerliste, 5][[i]]]], {i, 1, 11}];
Grid[Partition[
Table[ListPlot[utbrudd1[[i]], Joined -> True, PlotRange -> {0, 35},
ImageSize -> 200], {i, 1, 11}], UpTo[4]]]
mean = Transpose[{dødsliste[[All, 1]], Map[Mean[#] &, dødsliste[[All, 2]]]}];
lower = Transpose[{dødsliste[[All, 1]],
Map[Quantile[#, 0.25] &, dødsliste[[All, 2]]]}];
upper = Transpose[{dødsliste[[All, 1]],
Map[Quantile[#, 0.75] &, dødsliste[[All, 2]]]}];
plot1 = ListPlot[{mean, upper, lower}, PlotStyle -> {Blue, Blue, Blue},
Filling -> {2 -> {3}}, Joined -> True, PlotRange -> All,
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GridLinesStyle -> Black, Axes -> False, Frame -> True,
FrameLabel -> {"vaccination rate (per day)", "deaths"},
FrameStyle -> Directive[12, Black]]
mean = Transpose[{levearliste[[All, 1]],
Map[Mean[#] &, levearliste[[All, 2]]]}];
lower = Transpose[{levearliste[[All, 1]],
Map[Quantile[#, 0.25] &, levearliste[[All, 2]]]}];
upper = Transpose[{levearliste[[All, 1]],
Map[Quantile[#, 0.75] &, levearliste[[All, 2]]]}];
plot1b = ListPlot[{mean, upper, lower}, PlotStyle -> {Blue, Blue, Blue},
Filling -> {2 -> {3}}, Joined -> True, PlotRange -> All,
GridLinesStyle -> Black, Axes -> False, Frame -> True,
FrameLabel -> {"vaccination rate (per day)", "YLL"},
FrameStyle -> Directive[12, Black]]
mean = Transpose[{dødsliste[[All, 1]], Map[Mean[#] &, dødsliste[[All, 2]]]}];
lower = Transpose[{dødsliste[[All, 1]],
Map[Quantile[#, 0.025] &, dødsliste[[All, 2]]]}];
upper = Transpose[{dødsliste[[All, 1]],
Map[Quantile[#, 0.975] &, dødsliste[[All, 2]]]}];
plot1c = ListPlot[{mean, upper, lower}, PlotStyle -> {Blue, Blue, Blue},
Filling -> {2 -> {3}}, Joined -> True, PlotRange -> All,
GridLinesStyle -> Black, Axes -> False, Frame -> True,
FrameLabel -> {"vaccination rate (per day)", "deaths"},
FrameStyle -> Directive[12, Black]]
mean = Transpose[{levearliste[[All, 1]],
Map[Mean[#] &, levearliste[[All, 2]]]}];
lower = Transpose[{levearliste[[All, 1]],
Map[Quantile[#, 0.025] &, levearliste[[All, 2]]]}];
upper = Transpose[{levearliste[[All, 1]],
Map[Quantile[#, 0.975] &, levearliste[[All, 2]]]}];
plot1d = ListPlot[{mean, upper, lower}, PlotStyle -> {Blue, Blue, Blue},
Filling -> {2 -> {3}}, Joined -> True, PlotRange -> All,
GridLinesStyle -> Black, Axes -> False, Frame -> True,
FrameLabel -> {"vaccination rate (per day)", "YLL"},












(* lager nettverk *)
g = RandomGraph[H];
A = AdjacencyMatrix[g];
links = Drop[ArrayRules[A][[All, 1]], -1];
L[i_] :=
Map[{#} &,
Extract[links, Position[links[[All, 1]], _?(# == i &)]][[All, 2]]];
antallkontakter = Table[Length[L[i]], {i, 1, n}];
G = (Mean[





RandomChoice[grupper[[k]], aldersfordeling[[k]]], {k, 1, 10}]];
alder = {};




alder = Append[alder, RandomChoice[Join[gruppe5, gruppe6]]];
,
alder = Append[alder, RandomChoice[alder0]];
];
, {k, 1, Length[alder0]}];
forventetlevetid = gg /. zz -> alder;








smittende = Table[0, {n}];
k = RandomInteger[{1, n}];
smittende[[k]] = 1;




psmittende = Position[smittende, _?(# == 1 &)];
farge = Map[# -> Red &, Flatten[psmittende]];
plotliste = Append[plotliste, GraphPlot[g, VertexStyle -> farge]];




Prepend[Table[Table[0, {n}], {smittsomtid - 1}], smittende];
Do[
vaksinerperdag = RandomInteger[PoissonDistribution[vaksinerate]];
ksmitte = Flatten[Position[smittende, _?(# == 1 &)]];
nyimune = smittende;
vaksineliste = Reverse[SortBy[Delete[antallkontakterwp, pimune], First]];
If[Length[vaksineliste] >= vaksinerperdag,
Do[
nyimune[[vaksineliste[[kk, 2]]]] = 1;
vaksinert = Append[vaksinert, vaksineliste[[kk, 2]]];
, {kk, 1, vaksinerperdag}];
,
nyimune = Table[1, {n}];
];
imune = UnitStep[imune + nyimune - 1];
mulige =
Plus @@ Table[
MapAt[# + 1 &, Table[0, {n}], L[ksmitte[[j]]]], {j, 1,
Length[ksmitte]}];
probsmitte = 1 - (1 - \[Beta])^mulige;
probsmitte = probsmitte*(1 - imune);
If[Length[ksmitte] > 0 ,
nysmittede =
UnitStep[Sign[probsmitte - Table[RandomReal[], {Length[mulige]}]]];
nysmittede = UnitStep[nysmittede - smittetever - 1];
smittetever = UnitStep[smittetever + nysmittede - 1];
smittende =
smittende + UnitStep[Last[nysmittedeliste] - 1] - Last[smittendeliste];
smittendeliste = Drop[smittendeliste, -1];
smittendeliste = Prepend[smittendeliste, Last[nysmittedeliste]];
nysmittedeliste = Drop[nysmittedeliste, -1];
nysmittedeliste = Prepend[nysmittedeliste, nysmittede];
pnysmittende = Position[nysmittede, _?(# == 1 &)];
psmittende = Position[smittende, _?(# == 1 &)];
pimune = Position[imune, _?(# == 1 &)];




smittende + UnitStep[Last[nysmittedeliste] - 1] - Last[smittendeliste];
smittendeliste = Drop[smittendeliste, -1];
smittendeliste = Prepend[smittendeliste, Last[nysmittedeliste]];
nysmittede = Table[0, {n}];
nyetilfeller = Append[nyetilfeller, 0];
nysmittedeliste = Drop[nysmittedeliste, -1];







, {t, 1, tmax}];
referanse = 0.001;
døde = Plus @@ (referanse*d[alder]*smittetever);
taptelevear = Plus @@ (referanse*d[alder]*smittetever*forventetlevetid);
dliste = Append[dliste, døde];
lliste = Append[lliste, taptelevear];
nyetilfellerliste = Append[nyetilfellerliste, nyetilfeller];
, {teller, 1, 5}];
dødsliste = Append[dødsliste, {v, dliste}];
levearliste = Append[levearliste, {v, lliste}];




Table[Map[Mean[# + 0.] &,
Transpose[Partition[nyetilfellerliste, 5][[i]]]], {i, 1, 11}];
Grid[Partition[
Table[ListPlot[{utbrudd1[[i]], utbrudd2[[i]]}, PlotStyle -> {{Blue}, {Red}},
Axes -> False, Frame -> True,
FrameLabel -> {"time (days)", "New cases per day"},
FrameStyle -> Directive[Black, 11], Joined -> True, PlotRange -> {0, 35},
ImageSize -> 200], {i, 1, 11}], UpTo[4]]]
mean = Transpose[{dødsliste[[All, 1]], Map[Mean[#] &, dødsliste[[All, 2]]]}];
lower = Transpose[{dødsliste[[All, 1]],
Map[Quantile[#, 0.25] &, dødsliste[[All, 2]]]}];
upper = Transpose[{dødsliste[[All, 1]],
Map[Quantile[#, 0.75] &, dødsliste[[All, 2]]]}];
plot2 = ListPlot[{mean, upper, lower}, PlotStyle -> {Red, Red, Red},
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Filling -> {2 -> {3}}, Joined -> True, PlotRange -> All,
GridLinesStyle -> Black, Axes -> False, Frame -> True,
FrameLabel -> {"vaccination rate (per day)", "deaths"},
FrameStyle -> Directive[16, Black]];
mean = Transpose[{levearliste[[All, 1]],
Map[Mean[#] &, levearliste[[All, 2]]]}];
lower = Transpose[{levearliste[[All, 1]],
Map[Quantile[#, 0.25] &, levearliste[[All, 2]]]}];
upper = Transpose[{levearliste[[All, 1]],
Map[Quantile[#, 0.75] &, levearliste[[All, 2]]]}];
plot2b = ListPlot[{mean, upper, lower}, PlotStyle -> {Red, Red, Red},
Filling -> {2 -> {3}}, Joined -> True, PlotRange -> All,
GridLinesStyle -> Black, Axes -> False, Frame -> True,
FrameLabel -> {"vaccination rate (per day)", "YLL"},
FrameStyle -> Directive[16, Black]];
figa = Show[plot1, plot2, ImageSize -> 300,
Epilog -> Inset[Style["A", 18], Scaled[{0.9, 0.9}]]];
figb = Show[plot1b, plot2b, ImageSize -> 300,
Epilog -> Inset[Style["B", 18], Scaled[{0.9, 0.9}]]];
FIG1 = Show[Rasterize[Grid[{{figa, figb}}], RasterSize -> 2000],
PlotLabel ->
Style["Network: Uniform Graph Distribution, R0=1.5, N=300", Black, 12],
ImageSize -> 800]
mean = Transpose[{dødsliste[[All, 1]], Map[Mean[#] &, dødsliste[[All, 2]]]}];
lower = Transpose[{dødsliste[[All, 1]],
Map[Quantile[#, 0.025] &, dødsliste[[All, 2]]]}];
upper = Transpose[{dødsliste[[All, 1]],
Map[Quantile[#, 0.975] &, dødsliste[[All, 2]]]}];
plot2c = ListPlot[{mean, upper, lower}, PlotStyle -> {Red, Red, Red},
Filling -> {2 -> {3}}, Joined -> True, PlotRange -> All,
GridLinesStyle -> Black, Axes -> False, Frame -> True,
FrameLabel -> {"vaccination rate (per day)", "deaths"},
FrameStyle -> Directive[16, Black]];
mean = Transpose[{levearliste[[All, 1]],
Map[Mean[#] &, levearliste[[All, 2]]]}];
lower = Transpose[{levearliste[[All, 1]],
Map[Quantile[#, 0.025] &, levearliste[[All, 2]]]}];
upper = Transpose[{levearliste[[All, 1]],
Map[Quantile[#, 0.975] &, levearliste[[All, 2]]]}];
plot2d = ListPlot[{mean, upper, lower}, PlotStyle -> {Red, Red, Red},
Filling -> {2 -> {3}}, Joined -> True, PlotRange -> All,
GridLinesStyle -> Black, Axes -> False, Frame -> True,
FrameLabel -> {"vaccination rate (per day)", "YLL"},
FrameStyle -> Directive[16, Black]];
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figc = Show[plot1c, plot2c, ImageSize -> 300,
Epilog -> Inset[Style["A", 18], Scaled[{0.9, 0.9}]]];
figd = Show[plot1d, plot2d, ImageSize -> 300,
Epilog -> Inset[Style["B", 18], Scaled[{0.9, 0.9}]]];
FIG2 = Show[Rasterize[Grid[{{figc, figd}}], RasterSize -> 2000],
PlotLabel ->
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